JPRN-UMIN000036560招募中未知
The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM - The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM
ippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology0 个研究点目标入组 30 人开始时间: 2019年5月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. pregnant woman or lactating mother 2. poorly controlled heart failure 3. poorly controlled hypertension or diabetes 4. severe renal disorder 5. decompensated liver cirrhosis 6. other liver diseases, including autoimmune hepatitis, primary biliary cholangitis and alcoholic hepatitis, liver failure 7. positive result for hepatitis C antibody, hepatitis B surface antigen and antibody to human immunodeficiency virus type-1 8. hypercarcemia 9. hyperparathyroidism 10. Judged by investigator not to be appropriate for inclusion in this study
研究者
相似试验
已完成
4 期
A clinical trial to compare the effects of Canagliflozin and Sitagliptin in Patients with Type 2 Diabetes mellitus on a background metformin therapy.CTRI/2019/02/017435SRM College of Pharmacy40
已完成
不适用
The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease.onalcoholic fatty liver disease type 2 diabetes mellitusJPRN-UMIN000023044Kyoto prefetural University of Medicine20
已完成
不适用
Study of the beneficial effect of Canagliflozin on nocturnal home BP in Japanese T2DM patients(SHIFT-J STUDY)Type 2 diabetes mellitus patients with hypertensionJPRN-UMIN000023487Jichi Medical University School of Medicine100
尚未招募
不适用
Effect of canagliflozin as an alternative drug from DPP-4 inhibitor on heart failure with diabetis melltus : the pilot study "Can canagliflozin HAve Not only hypoGlycemic but cardiac supportive Effect?"chronic heart failure with type 2 diabetis mellitusJPRN-UMIN000031563Osaka Rosai Hospital40
进行中（未招募）
1 期
The effect of canagliflozin 300mg on glucose levels in people without diabetes after weight loss surgery.EUCTR2019-004041-32-GBniversity of Leicester24